帕金森病内科治疗新策略  

New strategies in treatment of parkinson's disease

作　　者：樊文辉[1] 陈彪[1] 

机构地区：[1]首都医科大学宣武医院北京市老年病医学研究中心神经生物室,北京100053

出　　处：《基础医学与临床》2005年第8期703-706,共4页Basic and Clinical Medicine

基　　金：国家科技攻关计划(2004BA702B02);国家重点基础研究发展计划(G2000057005)

摘　　要：目前左旋多巴仍是治疗帕金森病的最有效药物,但所有的治疗措施仍停留在对症治疗阶段,并且长期应用左旋多巴会产生难以纠正的症状波动及异动症。针对帕金森病发病机制的研究热点,多种抗氧化应激、延缓细胞凋亡、改善线粒体功能及持续性多巴胺受体刺激的药物逐渐被应用于对帕金森病的治疗,这些药物有望延缓疾病进程,更好的改善临床症状。Although levedopa remains the most effective drug for Parkinson＇s disease, there are some limitations of current PD therpy. For example, no drug is currently available to slow down or stop PD progression and current drug therapy is limited to symptomatic control of the motor symptoms of PD, most importantly, levedopa-induced motor fluctuation and dyskinesia are difficult to manage, so many new drugs are tested to interrupt the chains of pathogenesis of PD. Antioxidant, mitochondrial metabolism, slowing apoptosis drugs and continuous dopamigergic stimulation are tested with potential efficacyta limited slow down the development of PD and control symptoms without many complications.

关 键 词：神经保护 氧化应激 凋亡 治疗 

分 类 号：R742.5[医药卫生—神经病学与精神病学]